Angiogenesis in colorectal cancer: Prognostic and therapeutic implications

被引:76
作者
Giatromanolaki, Alexandra
Sivridis, Efthimios
Koukourakis, Michael I.
机构
[1] Democritus Univ Thrace, Sch Med, Dept Radiotherapy Oncol, Alexandroupolis 68100, Greece
[2] Democritus Univ Thrace, Sch Med, Dept Pathol, Alexandroupolis 68100, Greece
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2006年 / 29卷 / 04期
关键词
angiogenesis; angiogenic factors; prognosis; colorectal cancer;
D O I
10.1097/01.coc.0000221317.56731.4e
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Angiogenesis is important for tumor growth and metastasis. This account reviews the clinicopathological studies conducted in the field of angiogenesis in colorectal cancer, the methods of assessing vascular-related characteristics in tissue sections and provides a background for the usefulness of antiangiogenic policies along with chemotherapy and radiotherapy. Highly angiogenic colorectal tumors are associated with aggressive histopathological features and poor patients' survival. Similarly, factors stimulating angiogenesis, such as vascular endothelial growth factor (VEGF), thymidine phosphorylase (TP), and others, are commonly related to increased vascular density (VD) and, therefore, to an unfavorable clinical course. Anti-VEGF agents have improved prognosis in patients with metastatic colorectal cancer, when added to standard chemotherapy. It is expected that, in addition to adjuvant chemotherapy and radiotherapy, agents blocking the stimulatory effect of VEGF on endothelial cells would prove beneficial to the patient.
引用
收藏
页码:408 / 417
页数:10
相关论文
共 147 条
[1]   Endostatin: The logic of antiangiogenic therapy [J].
Abdollahi, A ;
Hlatky, L ;
Huber, PE .
DRUG RESISTANCE UPDATES, 2005, 8 (1-2) :59-74
[2]  
Adachi Y, 2001, INT J CANCER, V95, P290, DOI 10.1002/1097-0215(20010920)95:5<290::AID-IJC1050>3.0.CO
[3]  
2-I
[4]   Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma [J].
Akbulut, H ;
Altuntas, F ;
Akbulut, KG ;
Ozturk, G ;
Cindoruk, M ;
Unal, E ;
Icli, F .
CYTOKINE, 2002, 20 (04) :184-190
[5]  
Aoki T, 2002, ONCOL REP, V9, P1267
[6]   LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan [J].
Banerji, S ;
Ni, J ;
Wang, SX ;
Clasper, S ;
Su, J ;
Tammi, R ;
Jones, M ;
Jackson, DG .
JOURNAL OF CELL BIOLOGY, 1999, 144 (04) :789-801
[7]   American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J].
Benson, AB ;
Schrag, D ;
Somerfield, MR ;
Cohen, AM ;
Figueredo, AT ;
Flynn, PJ ;
Krzyzanowska, MK ;
Maroun, J ;
McAllister, P ;
Van Cutsem, E ;
Brouwers, M ;
Charette, M ;
Haller, DG .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3408-3419
[8]   Tumour markers as early predictors of response to chemotherapy in advanced colorectal carcinoma [J].
Berglund, Å ;
Molin, D ;
Larsson, A ;
Einarsson, R ;
Glimelius, B .
ANNALS OF ONCOLOGY, 2002, 13 (09) :1430-1437
[9]   Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells [J].
Bischof, M ;
Abdollahi, A ;
Gong, P ;
Stoffregen, C ;
Lipson, KE ;
Debus, J ;
Weber, KJ ;
Huber, PE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (04) :1220-1232
[10]   Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine [J].
Bocci, G ;
Danesi, R ;
Marangoni, G ;
Fioravanti, A ;
Boggi, U ;
Esposito, I ;
Fasciani, A ;
Boschi, E ;
Campani, D ;
Bevilacqua, G ;
Mosca, F ;
Del Tacca, M .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2004, 498 (1-3) :9-18